Physician profile
Gregory B Clarke
NPI 1881671766
$1,328.60
in general payments reported to CMS, 2019-2025
13 companies · $287 in 2025
The $287 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $43.48 · 2021: $26.52 · 2022: $27.01 · 2023: $183 · 2024: $453 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $801 · Education: $99.99 · Travel and Lodging: $21.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $801.23 |
| Education | $99.99 |
| Travel and Lodging | $21.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $589.98 | 2023-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Novartis Pharmaceuticals Corporation | $249.82 | 2019-2024 | |
| Amgen INC. | $168.37 | 2019-2025 | Repatha |
| Teva Pharmaceuticals USA, INC. | $99.99 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $47.44 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $36.60 | 2019 | |
| Janssen Pharmaceuticals, INC | $33.53 | 2019 | |
| Abbott Laboratories | $27.01 | 2022 | |
| Heartflow, INC. | $23.19 | 2025 | |
| Novo Nordisk INC | $15.17 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.84 | 2020 | |
| Alnylam Pharmaceuticals INC. | $12.05 | 2019 | |
| Pfizer INC. | $11.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Clarke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.